Calcium buffering proteins play a critical role in maintaining calcium homeostasis in neurons. These proteins including calbindin D-28k, parvalbumin, and calretinin are essential for protecting neurons against calcium-mediated excitotoxicity and oxidative stress. Changes in the expression and function of these proteins are implicated in the selective vulnerability of specific neuronal populations in neurodegenerative diseases.
| Protein |
Gene |
Calcium Affinity |
Neuron Type |
| Calbindin D-28k |
CALB1 |
High (Kd ~10⁻⁶ M) |
Purkinje cells, hippocampal interneurons |
| Parvalbumin |
PVALB |
Medium (Kd ~10⁻⁶ M) |
Fast-spiking interneurons |
| Calretinin |
CALB2 |
Low (Kd ~10⁻⁵ M) |
Diverse interneuron populations |
Calcium buffering proteins work by binding free calcium ions, thereby reducing the concentration of free calcium in the cytosol and preventing calcium-dependent deleterious processes. The buffering capacity (κ) determines how effectively a neuron can handle calcium loads:
- Calbindin D-28k: High buffering capacity, can bind ~6 Ca²⁺ ions per molecule
- Parvalbumin: Medium buffering capacity, ~2 Ca²⁺ binding sites
- Calretinin: Lower buffering capacity but faster kinetics
flowchart TD
A[Ca²⁺ Influx] --> B[Voltage-gated Ca²⁺ channels]
A --> C[NMDA receptors]
A --> D[AMPA receptors]
B --> E[Free cytosolic Ca²⁺]
C --> E
D --> E
E --> F{Neuronal Ca²⁺ Buffering}
F --> G[Calbindin D-28k]
F --> H[Parvalbumin]
F --> I[Calretinin]
G --> J[Ca²⁺ Bound]
H --> J
I --> J
J --> K[Normal Signaling]
E --> L[Excess Free Ca²⁺]
L --> M[Calpain Activation]
M --> N[Mitochondrial Dysfunction]
N --> O[Oxidative Stress]
O --> P[Apoptosis/Necrosis]
K --> Q[Neuroprotection]
In Alzheimer's disease, the expression of calcium buffering proteins is altered:
- Calbindin: Reduced in hippocampal CA1 pyramidal neurons, correlating with memory impairment
- Parvalbumin: Decreased in cortical and hippocampal interneurons
- Mechanism: Aβ oligomers can directly affect calcium homeostasis and reduce buffering protein expression through transcriptional dysregulation
The loss of calbindin in vulnerable neurons makes them more susceptible to calcium-mediated toxicity from amyloid-beta interactions with NMDA receptors.
Selective vulnerability of dopaminergic neurons in the substantia nigra pars compacta (SNc) relates to calcium buffering:
- Low calbindin expression in SNc dopamine neurons correlates with vulnerability
- VTA dopamine neurons express higher calbindin and are more resistant
- Parvalbumin expression is reduced in PD brains
- Mechanism: LRRK2 mutations and α-synuclein aggregation impair calcium handling
Motor neuron vulnerability in ALS involves calcium buffering deficits:
- Reduced calbindin and parvalbumin in spinal motor neurons
- Increased calcium influx through hyperactive NMDA receptors
- Mechanism: SOD1 mutations and TDP-43 pathology affect calcium homeostasis
Striatal medium spiny neurons (MSNs) show calcium buffering abnormalities:
- Mutant huntingtin directly affects expression of calcium buffering proteins
- Reduced calbindin in striatal neurons correlates with disease progression
- Enhanced excitotoxicity due to impaired calcium handling
| Strategy |
Target |
Approach |
| Upregulation |
CALB1, PVALB |
Gene therapy, neurotrophic factors |
| Calcium modulation |
VGCC, NMDAR |
Channel blockers, modulators |
| Antioxidant |
ROS generators |
Mitochondrial protectants |
- Calcium channel blockers (e.g., isradipine) show promise in protecting vulnerable neurons
- Calpain inhibitors prevent calcium-dependent protease activation
- Memantine is an FDA-approved NMDA antagonist used in AD
| Protein |
Function |
Therapeutic Target |
| CALB1 |
High-affinity calcium binding |
Gene therapy |
| PVALB |
Fast-spiking neuron protection |
Small molecule inducers |
| CALB2 |
Moderate buffering |
Unknown |
| S100A10 |
p11 subunit, calcium signaling |
Antidepressant interactions |
| Calsequestrin |
ER calcium storage |
Not yet targeted |
- Serum calbindin: Potential biomarker for neuronal injury
- CSF calcium-binding proteins: Under investigation
- PET ligands: Targeting calcium channels in vivo
Calcium buffering proteins interact with multiple neurodegenerative pathways:
- Neuroinflammation: Cytokines can downregulate buffering protein expression
- Mitochondrial dysfunction: Calcium overload leads to mitochondrial permeability transition
- Excitotoxicity: NMDA receptor overactivation overwhelms buffering capacity
- Oxidative stress: ROS can modify calcium binding proteins
- Baimbridge et al., Calcium-binding proteins in the nervous system (1992)
- Mattson, Calcium and neurodegeneration (2007)
- García-López et al., Calbindin and parvalbumin in neurodegenerative diseases (2011)
- Kawamoto et al., Calcium dysregulation in Alzheimer's disease (2022)
- Surmeier et al., Calcium and Parkinson's disease (2017)
- Van Den Bosch et al., Calcium dysregulation in ALS (2020)
- Sumbria et al., Calcium buffering proteins as therapeutic targets (2021)
- Heizmann, S100 proteins in the brain (2019)